Nuvalent, Inc.
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domai…
Biotechnology
US, Cambridge [HQ]
NUVL/Financials
Segments · Problems · Premarket · Compliance
Segment Analysis
Segments · Problems · Premarket · ComplianceSegment Analysis
Revenue · By Business Segment
These hierarchically ordered segment trees are sourced from the most recent 10-K filings, directly from the SEC.
Not available for NUVL
Revenue · By Area
This map and table comes from the most recent 10-K filings, directly from the SEC.
Not available for NUVL